Cogent Biosciences, Inc.
COGT
$11.40
-$0.02-0.18%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 45.49M | 43.28M | 41.10M | 38.75M | 36.88M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 288.47M | 275.94M | 260.43M | 244.60M | 227.30M |
| Operating Income | -288.47M | -275.94M | -260.43M | -244.60M | -227.30M |
| Income Before Tax | -269.50M | -255.86M | -242.30M | -227.05M | -212.17M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -269.50 | -255.86 | -242.30 | -227.05 | -212.17 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -269.50M | -255.86M | -242.30M | -227.05M | -212.17M |
| EBIT | -288.47M | -275.94M | -260.43M | -244.60M | -227.30M |
| EBITDA | -285.98M | -273.49M | -258.01M | -242.22M | -224.96M |
| EPS Basic | -2.48 | -721.35 | -721.36 | -721.37 | -721.36 |
| Normalized Basic EPS | -1.52 | -450.81 | -450.85 | -450.85 | -450.84 |
| EPS Diluted | -2.48 | -721.35 | -721.36 | -721.37 | -721.36 |
| Normalized Diluted EPS | -1.52 | -450.81 | -450.85 | -450.85 | -450.84 |
| Average Basic Shares Outstanding | 434.24M | 320.94M | 296.22M | 272.22M | 247.73M |
| Average Diluted Shares Outstanding | 434.24M | 320.94M | 296.22M | 272.22M | 247.73M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |